Liposomal delivery systems for intestinal lymphatic drug transport

다국어 초록 (Multilingual Abstract)

Intestinal lymphatic drug delivery has been widely studied because drugs can bypass the first-pass metabolism in the liver via the lymphatic route, which increases oral bioavailability. Various lipid-based nanoparticles have been used to deliver hydrophobic drugs to the lymphatic pathway. This review focuses on the liposomal delivery systems used for intestinal lymphatic drug transport. Liposomal formulations have attracted particular attention because they can stimulate the production of chylomicrons and the incorporated drugs readily associate with enterocytederived chylomicrons, enhancing lymphatic drug transport. We believe that a full understanding of their contribution to intestinal drug translocation will lead to effective oral delivery with liposomal formulations.

참고문헌 (Reference)

1 Zhou C, "The preparation of a complex of insulin-phospholipids and their interaction mechanism" 18 : 541-548, 2012

2 Dahan A, "The oral absorption of phospholipid prodrugs : In vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration" 126 : 1-9, 2008

3 Torchilin VP, "Recent advances with liposomes as pharmaceutical carriers" 5 : 145-160, 2005

4 이기영, "Preparation and Mucoadhesive Test of CSA-loaded Liposomes with Different Characteristics for the Intestinal Lymphatic Delivery" 한국생물공학회 10 (10): 516-521, 2005

5 Fricker G, "Phospholipids and lipid-based formulations in oral drug delivery" 27 : 1469-1486, 2010

6 Thanou M, "Oral drug absorption enhancement by chitosan and its derivatives" 52 : 117-126, 2001

7 Attili-Qadri S, "Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption" 110 : 17498-17503, 2013

8 Iwanaga K, "Oral delivery of insulin by using surface coating liposomes : Improvement of stability of insulin in GI tract" 157 : 73-80, 1997

9 Li X, "Novel mucus-penetrating liposomes as a potential oral drug delivery system : preparation, in vitro characterization, and enhanced cellular uptake" 6 : 3151-3162, 2011

10 Takeuchi H, "Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats" 86 : 235-242, 2003

11 Andar AU, "Microfluidic preparation of liposomes to determine particle size influence on cellular uptake mechanisms" 31 : 401-413, 2014

12 Kisel MA, "Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin : studies in the rat" 216 : 105-114, 2001

13 Kim H, "Liposomal formulations for enhanced lymphatic drug delivery" 8 : 96-103, 2013

14 Allen TM, "Liposomal drug delivery systems : From concept to clinical applications" 65 : 36-48, 2013

15 Charman WN, "Lipids, lipophilic drugs, and oral drug delivery—Some emerging concepts" 89 : 967-978, 2000

16 Porter CJH, "Lipids and lipid-based formulations : optimizing the oral delivery of lipophilic drugs" 6 : 231-248, 2007

17 Shi Y, "Lipid metabolic enzymes : emerging drug targets for the treatment of obesity" 3 : 695-710, 2004

18 Porter CJH, "Intestinal lymphatic drug transport : an update" 50 : 61-80, 2001

19 Fang G, "Improved oral bioavailability of docetaxel by nanostructured lipid carriers : in vitro characteristics, in vivo evaluation and intestinal transport studies" 5 : 437-96447, 2015

20 Wasan KM, "Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs : implications for drug discovery" 7 : 84-99, 2008

21 Niu M, "Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats : The effect of cholate type, particle size and administered dose" 81 : 265-272, 2012

22 Khan MSY, "Glyceride derivatives as potential prodrugs : synthesis, biological activit y and kinetic studies of glyceride derivatives of mefenamic acid" 60 : 110-114, 2005

23 Trevaskis NL, "From sewer to saviour — targeting the lymphatic system to promote drug exposure and activity" 14 : 781-803, 2015

24 Charman WNA, "Estimating the maximum potential for intestinal lymphatic transport of lipophilic drug molecules" 34 : 175-178, 1986

25 Murakami M, "Enteral siRNA delivery technique for therapeutic gene silencing in the liver via the lymphatic route" 5 : 1-13, 2015

26 Takeuchi H, "Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes" 13 : 896-901, 1996

27 Ling SSN, "Enhanced oral bioavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes" 32 : 335-345, 2006

28 Niu M, "Enhanced oral absorption of insulin-loaded liposomes containing bile salts : A mechanistic study" 460 : 119-130, 2014

29 Paliwal R, "Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate" 29 : 181-188, 2009

30 Huang Y-B, "Elastic liposomes as carriers for oral delivery and the brain distribution of(+)-catechin" 19 : 709-718, 2011

31 Caliph SM, "Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymphcannulated and non-cannulated rats" 89 : 1073-1084, 2000

32 Redgrave TG, "Chylomicron metabolism" 32 : 79-82, 2004

33 Goldberg M, "Challenges for the oral delivery of macromolecules" 2 : 289-295, 2003

34 Yoo J-W, "Bio-inspired, bioengineered and biomimetic drug delivery carriers" 10 : 521-535, 2011

35 Ali Khan A, "Advanced drug delivery to the lymphatic system : lipid-based nanoformulations" 8 : 2733-2744, 2013

36 Khoo S-M, "A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine" 90 : 1599-1607, 2001